Interpace Diagnostics Group Inc  

(Public, NASDAQ:IDXG)   Watch this stock  
Find more results for IDXG
1.22
+0.01 (0.83%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.18 - 1.25
52 week 0.70 - 19.80
Open 1.22
Vol / Avg. 714,506.00/1.30M
Mkt cap 32.76M
P/E 0.40
Div/yield     -
EPS 3.02
Shares 26.85M
Beta 1.61
Inst. own 10%
Nov 13, 2017
Q3 2017 Interpace Diagnostics Group Inc Earnings Call - Webcast
Sep 11, 2017
Interpace Diagnostics Group Inc at Rodman & Renshaw Global Investment Conference
Sep 6, 2017
Interpace Diagnostics Group Inc at Liolios Group Gateway Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -80.60% -64.27%
Operating margin -73.66% -49.23%
EBITD margin - 10.73%
Return on average assets -26.09% -15.36%
Return on average equity -37.36% -85.95%
Employees 61 -
CDP Score - -

Address

Morris Corporate Center 1 , Building C, 300 Interpace Parkway
PARSIPPANY, NJ 07054
United States - Map
+1-412-2246100 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Officers and directors

Stephen J. Sullivan Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Jack E. Stover CPA President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
James Early Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Age: 63
Bio & Compensation  - Reuters
Felice Schnoll-Sussman Director
Bio & Compensation  - Reuters
Joseph D. Keegan Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters